Read More

Reported Late Tuesday, Mesoblast Announces Top-Line Long-Term Survival Results For Remestemcel-L From Its Pivotal Phase 3 Trial Through 4-Years In Children With Steroid-Refractory Acute Graft vs Host Disease

Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001 Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in

MESO

Read More

Mesoblast Announced Single Intervention With Rexlemestrocel-l Improves Left Ventricular Ejection Fraction at 12 Months, Preceding Long-term Reduction in Major Adverse Cardiovascular Events

Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that treatment of HFrEF patients with rexlemestrocel-L, its allogeneic "off-the-shelf" product candidate for the treatment of chronic heart failure with reduced ejection fraction, resulted in greater improvement in the pre-specified analysis of left ventricular ejecti

MESO